Skip to main content

Johnson & Johnson Creates Trial Drug Bioethics Panel

Johnson & Johnson has appointed a leading bioethicist to head a panel to determine how to handle requests from people who are critically ill and want access to promising drugs before they are approved.

Lead image for this article

Johnson & Johnson has appointed a leading bioethicist to head a panel to determine how to handle requests from people who are critically ill and want access to promising drugs before they are approved. The move, which may spur similar efforts by other drug companies, comes amid increasingly high-profile social media campaigns by desperate patients. (The New York Times)

The Texas Tribune Member Drive Fall 2020 banner

This public-service journalism is made possible by readers like you.

Donate now